Tumor Models for Small & Large Molecule Drug Discovery

WuXi Biology has a significant experience in oncology drug discovery. We offer a large collection and tumors model for small & large molecule drug discovery.

virion particles, virus

Cell Line-derived Xenograft (CDX) Tumor Models

  • 77+ cell lines derived from PDX models
  • Available data of sensitivities to SOC (standard of care)
  • Imaging-based orthotopic/metastatic tumor models
  • Brain/bone metastatic models of lung/breast cancer cell lines

320+ Validated Models Covering 30 Tumor Types

Cancer Cell Line-Derived Xenograft (CDX)

BladderT24/83*, RT112/84* , UM-UC-3*, J82*, HT1197, HT1376, 5637, NBT-II, KMBC-2, SW780, SCaBER, RT-4
Brain U87*, LN-229*, D283*, T98G*, U118MG*, SK-N-SH, Daoy
BreastCal51*, BT-474*, HCC1954*, MDA-MB-231*, MDA-MB-468*, HCC1806*, MCF7*, HCC1937, MDA-MB-436*, SUM-52PE, JIMT-1*, MDA-MB-361*, HCC-70*, SUM 159PT, T47D*, HCC1428, ZR-75-1*, MT-3, DU4475*, BT-20, MFM-223, HCC1187, HCC1569, HCC1599, BT-483, HCC1500, MDA-MB-453, SUM149PT
Cervical SW756*, Ca Ski, ME180
CholangiocarcinomaHuCCT1
Colorectal Colo205*, HT29*, HCT-116*, HCT-15*, LS180* , LS174T*, SW620*, HT55*, DLD-1*, Lovo*, COLO-320DM, RKO, Caco-2, T84, WiDr, SW480*, SW 48, LS411N, COLO 201, GP2D, GP5D, SW837*, SW1463*, KM12*, Colo678, NCI-H508, HCT-8, RCM1, LS513, MDST8, LS1034, SW948
DuodenalHuTu80
EsophagealT.Tn, OE21*, EC9706*, OE19*, KYSE-520*, KYSE-150*
Endometrial AN3 CA*, RL95-2, HEC-1, MFE-280
Gastric NUGC4*, SNU-1*, SNU-16*, NCI-N87*, SNU-5, MKN45*, HS 746T*, KATO-III*, HGC-27, GIST-T1*, AGS
Head & NeckCal 27*, RPMI2650, Fadu*, Detroit 562, HSC-2
LeukemiaHEL 92.1.7*, MV4-11*, CCRF-CEM,  HL-60*, K562*, KG-1, MOLT-4*, Kasumi-1*, Nalm-6*, THP-1, SET-2* ,PL-21, RS4;11*, MOLM-13*, MEG-01, KU812*, MOLM-14
LiverBEL-7404*, Hep3B*, Huh 7*, HepG2*, SNU-398, JHH-7*, MHCC97H*, SK-HEP-1*, Huh-1
LungNCI-H1650, NCI-H226*, NCI-H460*, PC9*, A549*, Calu-1, Calu-6*, HCC1599, A427*, NCI-H647, MSTO-211H,  NCI-H292*, NCI-H322, NCI-H358*, NCI-H441*, NCI-H520, NCI-H1975*, NCI-H2228*, SK-MES-1, NCI-H1299, HCC-827*, HCC4006, NCI-H1703, NCI-H727, NCI-H2122*, DV-90, NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77 , Calu-3*, NCI-H2170*, NCI-H820*, NCI-H23*, NCI-H1568, NCI-H1944, NCI-H2023, NCI-H2030*, NCI-H2126, NCI-H838, NCI-H1838*, DMS114*, NCI-H211*, NCI-H209*, NCI-H2286*, NCI-H596, HCC15, HCC44*, NCI-H1373*, SW1573, LCLC-97TM1, HCC1588, NCI-H1048, NCI-H1581, NCI-H1781, NCI-H1963, COLO699, NCI-H2135, EBC-1*, NCI-H2172, LU99, DMS53,NCI-H1155, NCI-H1355, NCI-H1395, NCI-H522, NCI-H650, SW900, NCI-H1993*, NCI-H2110, NCI-H146*, NCI-H1623, NCI-H1770, NCI-H2347
Lung (small cell)NCI-H69*, NCI-H1417*, NCI-H446, NCI-H526*, NCI-H82, SHP-77, DMS114*, NCI-H211*, NCI-H209*, NCI-H2286, NCI-1048, NCI-H1963
Lymphoma Daudi*, SU-DHL-2*, SU-DHL-4*, SU-DHL-6, SU-DHL-10, Granta-519*, Maver-1*, Mino*, NAMALWA, Raji*, Ramos*, RL, WSU-DLCL2*, Z-138, U937, DoHH2*, Farage*, Pfeiffer*, REC-1*, Toledo, HuT78*, JeKo-1, CCRF-SB (ALL) *, SU-DHL-1, OCI-LY3, HBL-1*, OCI-LY7, KARPAS299*, HH, H9, KARPAS-422, SUPT1
MelanomaA375*, SK-MEL-24, SK-MEL-28, COLO 829*, SK-MEL-5 , MDA-MB-435S, MeWo, SK-MEL-3, A2058*, MP41, SK-MEL-2
Mesothelioma cancerNCI-H226*, MSTO-211H
MyelomaKMS-28BM, KMS-11, MOLP-8*, NCI-H929*, RPMI 8226*, MM.1S*, OPM-2*, MM.1R
NasopharyngealC666-1
NeuroblastomaCHP-134*, SK-N-AS*, BE(2)-C*
OvaryA2780*, SK-OV-3*, ES-2*, OVCAR-3*, TOV21G, OV90*, TOV112D, PA-1, CAOV3
PancreasBxPC3*, Mia-pa-ca-2*, KP4*, PANC-1*, CAPAN-1*, Panc 02.13*, AsPC-1, HPAC*, HPAFII, CFPAC-1, Panc 04.03
CAPAN-2, Mia-pa-ca-2 hCLDN18.2, Hs766T, SW1990
ProstatePC-3*, DU145*, LNCap*, VCaP* , 22RV.1*
Renal786-O*, ACHN, Caki-1, SK-NEP-1, A498
SarcomaHT1080, A673, KHOS/NP, 143B, SJSA-1*, SAOS-2, A204, G401, Aska-SS, HS-SY-II , Yamato-SS, SJCRH30, SK-ES-1
SkinA431*, MKL-1
Testicular EmbryonalNEC14
ThyroidTT*, FTC-238*, 8505C, xSW579
UterineSK-UT1
*validated with SOC compound

55 Experimental Metastasis Xenograft Models Covering 8 Tumor Types

Metastasis Xenograft Models

Cancer typesCell linesInoculation siteMetastatic
/target organs
Model types
BrainSK-N-SH-lucIntra-venousMultiple sitesMetastasis
BreastMCF7-luc, MDA-MB-231-luc-D3H2LN, HCC1954-lucS, MDA-MB-436-luc, xxT47D-lucIntra-cranialBrainEctopic
JIMT-1-lucS, HCC1954-lucSIntra-carotidBrainMetastasis
MDA-MB-231-luc-D3H2LNIntra-cardiacMultiple sitesMetastasis
JIMT-1-luc, HCC1954-lucS, MDA-MB-231-luc-D3H2LN, MDA-MB-436-luc, HCC1806-lucIntra-venousLungMetastasis
MCF-7-lucS, MDA-MB-231-luc, HCC1954-lucIntra-osseousBoneEctopic
MCF-7-lucS, MDA-MB-231-luc-D3H2LN, JIMT-1-luc-gfpIntra-caudal arterialBoneMetastasis
MDA-MB-231-lucIntra-peritonealMultiple sitesMetastasis
ColonSW620-lucIntra-liverEctopic
GastricNCI-N87-lucSIntra-cranialBrainMetastasis
LungNCI-H1975-lucS, NCI-H2228-luc, NCI-H441-luc, NCI-H460-luc2, PC-9-lucS, PC-9 EGFR DTC-lucS , NCI-H1703-luc, NCI-H2122-luc Clone-16-11, NCI-H1373-luc, LU-01-0426Intra-cranialBrainEctopic
NCI-H1373-lucS, NCI-H1975-lucS, NCI-H2122-luc, PC-9-lucS, NCI-H292-lucIntra-carotidBrainMetastasis
PC-9-luc-BR (in vivo selected “brain-seeking” cell line) SIntra-cardiacBrainMetastasis
NCI-H292-luc, HCC827-lucIntra-venousMultiple sitesMetastasis
NCI-H1373-luc, NCI-H358-lucIntra-osseousBoneEctopic
MelanomaSK-MEL-3-luc, SK-MEL-5-luc, SK-MEL-24-luc, SK-MEL-28-luc, A375-lucIntra-cranialBrainEctopic
PancreasMIA-PaCa-2-luc, AMG510-R-xMiaPaCa-2-luc, ASPC-1-lucIntra-cranialBrainEctopic
ASPC-1-lucIntra-carotidBrainMetastasis
ProstatePC-3M-lucSIntra-osseousBoneEctopic
PC-3M-lucIntra-caudal arterialBoneMetastasis

46 Orthotopic/Disseminated Tumor Models Covering 15 Tumor Types

Organ-based Orthotopic Models of Solid Tumor Cell Lines

BreastMCF7-luc, MDA-MB-231-luc-D3H2LNS, HCC1954-luc
ColorectalColo205-luc2, HT29-luc2, HCT-116-luc2
DuodenalHuTu80-luc
GastricMGC-803-luc , NCI-N87-lucS
LiverHep3B-lucS, HepG2-lucS, BEL-7404-lucS
LungA549-luc, NCI-H460-luc2
OvarianA2780-cp-luc, SK-OV-3-luc
PancreasBxPC3-luc2, MIA-PaCa-2-lucS , AsPC-1-luc, PANC-1-luc
ProstateLNCaP-luc2, PC-3M-luc2S, LNCap.FGC-luc
RenalACHN-luc2, 786-O-luc
SarcomaHT1080-luc2, 143B-luc

IV Injection Disseminated Models of Hematopoietic Cancer Cell Lines

LeukemiaK562-luc-GFP, MOLT-4-luc2, Nalm-6-luc, MOLM13-lucS, THP-1-luc, MV4-11-lucS , HL-60-luc
LymphomaOCI-LY7-luc, Raji-luc, Raji-hPD-L1-luc, Mino, JEKO-1,MM.1S-luc
MyelomaRPMI-8226-luc

Patient-derived Xenograft (PDX) Tumor Models

Cancer Patient Derived Xenograft (PDX) Platform

Tumor TypeProfiledEstablished
Breast cancer2327
Cervical cancer47
Cholangiocarcinoma3542
Colorectal cancer107133
Cervical cancer47
Endometrial cancer44
Esophageal cancer6083
Gallbladder cancer810
Gastric cancer70101
HCC119230
Kidney cancer2436
Leiomyosarcoma44
Lung cancer | NSCLC | ACD8399
Lung cancer | NSCLC | SCC129138
Lung cancer | NSCLC | ASC99
Lung cancer | NSCLC | Large cell33
Lung cancer | SCLC1521
Lung cancer | Other2186
Lymphoma4751
Melanoma1623
Nasopharyngeal carcinoma2032
Osteosarcoma1823
Ovarian cancer1118
Pancreatic cancer5456
Urothelial carcinoma77
Uveal melanoma11
Thyroid cancer11

Cancer Patient Derived Xenograft (PDX) Platform

Tumor TypeProfiledEstablished
Breast cancer2327
Cervical cancer47
Cholangiocarcinoma3542
Colorectal cancer107133
Cervical cancer47
Endometrial cancer44
Esophageal cancer6083
Gallbladder cancer810
Gastric cancer70101
HCC119230
Kidney cancer2436
Leiomyosarcoma44
Lung cancer | NSCLC | ACD8399
Lung cancer | NSCLC | SCC129138
Lung cancer | NSCLC | ASC99
Lung cancer | NSCLC | Large cell33
Lung cancer | SCLC1521
Lung cancer | Other2186
Lymphoma4751
Melanoma1623
Nasopharyngeal carcinoma2032
Osteosarcoma1823
Ovarian cancer1118
Pancreatic cancer5456
Urothelial carcinoma77
Uveal melanoma11
Thyroid cancer11

Syngeneic tumor models

  • 87 Syngeneic models (mouse, rat, hamster) covering 20 cancer types
  • Comprehensive panel of orthotopic syngeneic tumor models
  • Responsiveness to immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4, etc.)
  • Tumor-infiltrating leukocytes (TILs) map
  • WES, RNA-seq and scRNA-seq characterization
syngeneic, tumor models, checkpoint, TILs, RNA-seq, scRNA-seq
Orthotopic/metastasis models marked in red; models with reference drug treatment data marked as S; models with gene expression/mutation profiling data marked GC (cell-line profiled), GT (tumor tissue profiled), or GC/T (both)

Genetically engineered models

  • 48 engineered cell lines based on construct overexpression or gene knock-in
  • Pharmacologically validated both in vitro and in vivo
  • Focusing on drug-resistant mutation introduction and IO-related checkpoint humanization
  • Example targets: EGFR, ROS1, ALK, RET, FLT3, BTK, Claudin18.2, PD-L1

hPBMC/HSC Humanized Models

hPBMC Humanized Models

  • Established models for immune-checkpoint inhibitor and bi-specific antibody candidates in a human-resembling immune system.
  • Annotation for both immune cells (phenotyping, biomarker, functions) and tumor cells (expression, mutation)
  • Different PBMC delivery systems (systemic injection or co-inoculation with tumor)

HSC Humanized Models

  • Available humanized models from CIEA, combined with WuXi PDX/CDX models.
  • Customizable with human cytokine transgenic mice (GM-CSF/hIL-3 or hIL-2) to improve the reconstitution of myeloid lineage.

Established CDX/PDX-hPBMC Models

hPBMC, tumor models
*Target efficacy validation

Human immune checkpoint gene KI mouse models

KI (Knock-in) mice offer the possibility to study clinical grade checkpoint antibodies targeting human checkpoints in the context of a fully functional immune system. WuXi Biology offers efficacy studies in different mouse strains with human targets KI in mice and cell line, and comprehensive flow cytometry to evaluate target expression and immune function.

  • Collection of various targets and background mouse strains
  • Validated with launched or most advanced clinical grade checkpoint antibodies
  • Double checkpoint KI mice customizable for combination (PD1 + OX40, PD1 + TIM3)
human immune checkpoint gene KI knock-in mouse models to study checkpoint antibodies

Immuno-avatar humanized models

  • Mouse models harboring human tumor and human immune ceils
  • Three different diagram of hPBMC humanization for mature T cell engraftment
  • HSC (CD34+) avatar and next generation immune avatar for multiple-lineage engraftment (Myeloid, NK, DC)
  • IO-CDX and IO-PDX models with cancer targets and HLA information

Drug-resistant models